Sol-Gel Technologies Ltd. (SLGL) Bundle
Ever wondered about the story behind Sol-Gel Technologies Ltd. (SLGL) and how it operates in the world of dermatology? This company is pioneering treatments for patients with severe skin conditions, but what exactly is their history, who owns them, and how do they make money? Keep reading to discover the ins and outs of Sol-Gel Technologies, from its innovative products like TWYNEO® and EPSOLAY® to its ongoing clinical trials and strategic partnerships.
Sol-Gel Technologies Ltd. (SLGL) History
Sol-Gel Technologies Ltd. Founding Timeline
Year established
Sol-Gel Technologies Ltd. was established in 1997.
Original location
The company's original location is in Ness Ziona, Israel.
Founding team members
The founders of Sol-Gel Technologies Ltd. are Dr. Moshiel Biton and Prof. David Avnir.
Initial capital/funding
Information regarding the initial capital or funding for Sol-Gel Technologies Ltd. is not readily available in the provided search results.
Sol-Gel Technologies Ltd. Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2003 | Commenced operations | Marked the beginning of the company's activities in the pharmaceutical industry. |
| 2017 | FDA approval for Twyneo | The FDA approved Twyneo, an acne treatment, marking a significant milestone. |
| 2020 | Expanded product pipeline | Sol-Gel Technologies broadened its focus to include various dermatological conditions beyond acne. |
Sol-Gel Technologies Ltd. Transformative Moments
- 2003: Operational Launch: The commencement of operations in 2003 was a transformative moment, transitioning the company from a research-oriented entity to an active participant in the pharmaceutical market.
- 2017: FDA Approval of Twyneo: The FDA approval of Twyneo in 2017 significantly validated Sol-Gel Technologies' research and development efforts, paving the way for commercialization and establishing credibility in the dermatology space.
- 2020: Diversification of Product Pipeline: The strategic decision to broaden the product pipeline in 2020 to include treatments for various dermatological conditions demonstrated adaptability and a commitment to addressing a wider range of patient needs.
To gain a deeper understanding of the company's financial status, explore Breaking Down Sol-Gel Technologies Ltd. (SLGL) Financial Health: Key Insights for Investors.
Sol-Gel Technologies Ltd. (SLGL) Ownership Structure
Sol-Gel Technologies Ltd. features a mix of institutional, insider, and retail ownership, influencing its corporate governance and strategic direction. More insights can be found here: Exploring Sol-Gel Technologies Ltd. (SLGL) Investor Profile: Who’s Buying and Why?
Sol-Gel Technologies Ltd.'s Current Status
Sol-Gel Technologies Ltd. is a public company, trading on the NASDAQ under the ticker symbol SLGL. As a public entity, it is subject to regulatory oversight and reporting requirements, ensuring transparency for investors and stakeholders.
Sol-Gel Technologies Ltd.'s Ownership Breakdown
The following table breaks down the ownership structure of Sol-Gel Technologies Ltd., providing a snapshot of the key stakeholders and their respective ownership percentages.
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Investors | 55.70% | Includes investment firms, mutual funds, and other institutions. |
| Insider Ownership | 13.78% | Shares held by company executives and board members. |
| Retail Investors | 30.52% | Individual investors holding shares of Sol-Gel Technologies Ltd. |
Sol-Gel Technologies Ltd.'s Leadership
The leadership team at Sol-Gel Technologies Ltd. is responsible for guiding the company's strategic vision and operational execution. Key members include:
- Tomer Rotem: Chief Executive Officer
- Alon Seri-Levy: Chief Financial Officer
- Dr. Shimon Mizrahi: Co-Founder & Chief Scientific Officer
This team brings together expertise in pharmaceuticals, dermatology, and business management, crucial for steering Sol-Gel Technologies Ltd. in the competitive pharmaceutical landscape. Their leadership is pivotal in driving the company's growth and innovation strategies.
Sol-Gel Technologies Ltd. (SLGL) Mission and Values
Sol-Gel Technologies Ltd. focuses on identifying, developing, and commercializing innovative, proprietary, and scientifically differentiated topical dermatological products. The company's mission is reflected in its commitment to addressing unmet patient needs through its unique microencapsulation technology.
Sol-Gel Technologies Ltd. Core Purpose
Official mission statement
While an explicit official mission statement for Sol-Gel Technologies Ltd. isn't available in the provided search results, their core purpose is evident in their activities and focus:
- Developing and commercializing topical dermatological products.
- Using microencapsulation technology to create innovative solutions.
- Addressing unmet needs in the dermatology space.
Vision statement
Similarly, a specific vision statement isn't provided in the search results. However, the vision can be inferred from their goals and achievements:
- To become a leader in innovative dermatological solutions.
- To improve patient outcomes through advanced topical treatments.
- To expand their portfolio of microencapsulated products.
Company slogan/tagline
There is no readily available official slogan or tagline in the search results. In place of a slogan, consider the essence of what they do:
- Microencapsulation for Enhanced Dermatology.
- Innovation in Topical Skin Solutions.
- Targeted Treatments, Visible Results.
For more in-depth information, visit: Mission Statement, Vision, & Core Values of Sol-Gel Technologies Ltd. (SLGL).
Sol-Gel Technologies Ltd. (SLGL) How It Works
Sol-Gel Technologies Ltd. (SLGL) is a clinical-stage specialty pharmaceutical company leveraging its silica-based microencapsulation technology to develop and commercialize topical dermatological drug products, enhancing treatment efficacy and reducing side effects.
Sol-Gel Technologies Ltd.'s Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| Twyneo | Acne vulgaris | Once-daily, non-antibiotic topical cream. |
| Epsolay | Papulopustular (subtype II) rosacea | Once-daily topical cream. |
| SGT-610 (Patidegib gel, 2%) | Gorlin Syndrome | Topically applied gel for the prevention of new basal cell carcinoma (BCC) lesions; currently in Phase 3 clinical trials. |
| SGT-210 (Topical erlotinib) | Pachyonychia Congenita (PC) and other rare hyperkeratinization disorders | Topical treatment for thickened skin and nails; completed Phase 1 clinical trial. |
| Generic Topical Dermatological Drug Products | Various skin conditions | Utilizes silica-based microencapsulation to improve tolerability and stability while maintaining efficacy. |
Sol-Gel Technologies Ltd.'s Operational Framework
Sol-Gel Technologies operates with a focus on:
- Identifying and Developing Dermatology Assets: SLGL identifies and develops promising dermatology assets.
- Enhancing Therapeutic Potential: The company leverages its expertise to enhance the trajectory of dermatological treatments.
- Delivering Innovative Formulations: SLGL delivers innovative formulations to patients.
- Microencapsulation Technology: The cornerstone of Sol-Gel's business model lies in its robust microencapsulation technology. This technology encapsulates drug substances within porous silica microcapsules, creating a protective barrier that not only controls the release rate but also safeguards the active compound from direct skin contact, potentially enhancing clinical outcomes and patient comfort.
- Partnerships: Sol-Gel is actively seeking to expand its pipeline by acquiring proven drug candidates and is open to licensing out its proprietary assets.
Sol-Gel Technologies Ltd.'s Strategic Advantages
Sol-Gel Technologies Ltd. has several strategic advantages:
- Proprietary Microencapsulation Technology: Their silica-based microencapsulation delivery system enhances drug tolerability and stability.
- Pipeline of Advanced Dermatological Drugs: Focus on developing solutions for both rare and common skin conditions.
- Strategic Partnerships: Collaborations with companies like Galderma and Searchlight Pharma.
- Competitive Pricing: SLGL has competitive pricing within the dermatological prescription market, with prices ranging between $350-$500 per treatment course. Patient assistance programs offer discounts up to 50% for eligible patients.
To gain more insights into the company's values, check out this link: Mission Statement, Vision, & Core Values of Sol-Gel Technologies Ltd. (SLGL).
Sol-Gel Technologies Ltd. (SLGL) How It Makes Money
Sol-Gel Technologies Ltd. (SLGL) generates revenue primarily through the development and commercialization of topical dermatological products.
Sol-Gel Technologies Ltd.'s Revenue Breakdown
As the information and data is not available publicly for 2024 fiscal year, a precise revenue breakdown by percentage is not possible. To understand Sol-Gel Technologies' revenue streams, it's important to consider their key products and licensing agreements.
In general, revenue streams for a company like Sol-Gel Technologies would typically include:
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Product Sales (TWYNEO, EPSOLAY, ZILXI) | Varies | Increasing |
| Licensing and Royalties | Varies | Dependent on Agreements |
Sol-Gel Technologies Ltd.'s Business Economics
Sol-Gel Technologies operates within the pharmaceutical industry, specifically focusing on dermatology. Their economic model relies on:
- Research and Development: Significant investment in creating novel topical drugs.
- Clinical Trials: Expenses related to proving the safety and efficacy of their products.
- Manufacturing and Supply Chain: Costs associated with producing and distributing the drugs.
- Marketing and Sales: Efforts to promote and sell their products to healthcare providers and patients.
- Regulatory Approvals: Navigating the FDA approval process, which can be lengthy and expensive.
Understanding the business economics also involves considering factors such as:
- Pricing Strategies: How they price their products to be competitive yet profitable.
- Market Demand: The prevalence of the dermatological conditions their products treat.
- Competition: The presence of other companies offering similar treatments.
Sol-Gel Technologies Ltd.'s Financial Performance
Analyzing Sol-Gel Technologies' financial performance requires looking at key metrics, although specific 2024 data is not available. Typically, this would include:
- Revenue Growth: How quickly their sales are increasing.
- Gross Margin: The profitability of their products after accounting for the cost of goods sold.
- Operating Expenses: Costs related to research and development, sales, and administration.
- Net Income/Loss: The bottom-line profitability of the company.
- Cash Flow: The amount of cash the company is generating.
These metrics help investors assess the company's financial health and growth potential. More insights about the company can be found here: Mission Statement, Vision, & Core Values of Sol-Gel Technologies Ltd. (SLGL).
Sol-Gel Technologies Ltd. (SLGL) Market Position & Future Outlook
Sol-Gel Technologies Ltd. is positioning itself for future growth within the dermatology market, focusing on innovative solutions for acne and other skin conditions. While specific market share data as of April 2025 is not available, understanding the competitive landscape, potential opportunities, and inherent risks is crucial for assessing the company's trajectory. For more insights, explore Mission Statement, Vision, & Core Values of Sol-Gel Technologies Ltd. (SLGL).
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Sol-Gel Technologies Ltd. | N/A | Focus on innovative, proprietary topical drug delivery technologies. |
| Galderma | N/A | Broad product portfolio and established market presence in dermatology. |
| Bausch Health Companies Inc. | N/A | Extensive range of dermatological products, including prescription and over-the-counter treatments. |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Potential FDA approvals for new acne and skin condition treatments. | Regulatory hurdles and potential delays in FDA approval processes. |
| Growing demand for effective and convenient topical treatments. | Competition from established players and generic alternatives. |
| Strategic partnerships to expand product reach and market penetration. | Uncertainties in clinical trial outcomes and commercialization success. |
Industry Position
Sol-Gel Technologies operates within the dynamic pharmaceutical and dermatology industries. Here are key factors influencing its industry standing:
- Innovation in Topical Drug Delivery: The company's proprietary microencapsulation technology offers a unique selling proposition.
- Focus on Dermatology: By concentrating on dermatological conditions, Sol-Gel can tailor its research and development efforts.
- Regulatory Landscape: Heavily influenced by FDA regulations and approval pathways for new drugs.
- Market Trends: Adapting to trends such as increasing demand for non-invasive cosmetic procedures and advanced skincare solutions.
Sol-Gel Technologies Ltd. (SLGL) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.